Modeling the spectrum of HIT pathobiology

HIT 病理学谱系建模

基本信息

  • 批准号:
    8358867
  • 负责人:
  • 金额:
    $ 7.85万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-05-01 至 2014-04-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The goal of this small grant application is to develop a research methodology for studies of Heparin-Induced Thrombocytopenia (HIT). HIT is a prothrombotic disorder caused by an allergic response to the anticoagulant drug, heparin. HIT is caused by antibodies directed towards a platelet protein, Platelet Factor 4 (PF4) and heparin (H). Because PF4/H antibodies can elicit life-threatening thrombotic complications in patients, experimental studies of disease pathogenesis have relied on animal models. Two distinct animal models have been developed to study HIT; one model studies thrombotic complications of HIT (murine HIT model) and the other, a murine immunization model developed by our lab to study the PF4/H immune response. In this R03 application, we propose to develop an integrated murine model for studies of human HIT pathogenesis. Based on preliminary studies, we hypothesize that pathogenicity of PF4/H antibodies is determined by the confluence of three factors, circulating antigen (PF4/H complexes), PF4/H Abs and activating platelet Fc RIIA receptors. We propose to test this hypothesis using one of two approaches relying on the presence of Fc RIIA expression (single transgenic model) with or without expression of hPF4 (double transgenic model). In the first approach, we will induce PF4/H antibodies in a single transgenic model (mice expressing hFc RIIA) with the goal of examining effects of antigen load, antibody titer and Fc RII expression. In the second approach, we wish to develop a "humanized" murine model using double transgenic mice expressing human (h)PF4 and hFc RIIA to examine the effects of hPF4 levels and hFcR expression on the immune response and disease expression. In pursuing this small research grant, we hope that these optimized murine models will facilitate future investigations on the mechanisms underlying evolution of pathogenic HIT antibodies. PUBLIC HEALTH RELEVANCE: These studies will study the most common drug-induced allergy, which occur with the blood thinner medication heparin. This allergy, called Heparin-Induced Thrombocytopenia is associated with life-threatening clotting complications. We propose to develop models for studying how this life-threatening allergic reaction happens in humans.
描述(由申请人提供):这项小额资助申请的目的是为肝素诱导的血小板减少症(HIT)的研究开发一种研究方法。HIT是由对抗凝药物肝素的过敏反应引起的血栓前障碍。HIT是由针对血小板蛋白、血小板因子4(PF 4)和肝素(H)的抗体引起的。由于PF 4/H抗体可在患者中引发危及生命的血栓性并发症,因此疾病发病机制的实验研究依赖于动物模型。已经开发了两种不同的动物模型来研究HIT;一种模型研究HIT的血栓形成并发症(鼠HIT模型),另一种是我们实验室开发的用于研究PF 4/H免疫应答的鼠免疫模型。在此R 03申请中,我们建议开发一种用于研究人类HIT发病机制的综合小鼠模型。基于初步研究,我们假设PF 4/H抗体的致病性由三个因素的汇合决定,即循环抗原(PF 4/H复合物)、PF 4/H抗体和活化血小板Fc RIIA受体。我们建议使用依赖于Fc RIIA表达的存在(单转基因模型)和hPF 4表达或不表达(双转基因模型)的两种方法之一来测试该假设。在第一种方法中,我们将在单一转基因模型(表达hFc RIIA的小鼠)中诱导PF 4/H抗体,目的是检查抗原负荷、抗体滴度和Fc RII表达的影响。在第二种方法中,我们希望使用表达人(h)PF 4和hFc RIIA的双转基因小鼠开发“人源化”鼠模型,以检查hPF 4水平和hFcR表达对免疫应答和疾病表达的影响。在追求这一小笔研究经费,我们希望这些优化的小鼠模型将有助于未来的致病性HIT抗体的进化机制的调查。 公共卫生相关性:这些研究将研究最常见的药物引起的过敏,这与血液稀释剂药物肝素发生。这种过敏称为肝素诱导的血小板减少症,与危及生命的凝血并发症有关。我们建议开发模型来研究这种危及生命的过敏反应如何在人类中发生。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Gowthami M Arepally其他文献

Anti-Phospholipid Syndrome (APS) Antibody (Ab)-Induced Thrombosis Can be Blocked By Platelet Factor 4 (PF4)-Directed Abs: A Novel Therapeutic Approach for APS?
  • DOI:
    10.1182/blood-2024-200849
  • 发表时间:
    2024-11-05
  • 期刊:
  • 影响因子:
  • 作者:
    Amrita Sarkar;Santosh K Yadav;Conroy O Field;Kandace Gollomp;Keith R. McCrae;Thomas L. Ortel;Yves Gruel;Jérôme Rollin;Gowthami M Arepally;Lubica Rauova;Douglas B. Cines;Mortimer Poncz
  • 通讯作者:
    Mortimer Poncz

Gowthami M Arepally的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Gowthami M Arepally', 18)}}的其他基金

Comparative studies of complement responses to ICs
补体对 IC 反应的比较研究
  • 批准号:
    10645672
  • 财政年份:
    2023
  • 资助金额:
    $ 7.85万
  • 项目类别:
Complement and Thrombosis in HIT
HIT 中的补体和血栓形成
  • 批准号:
    10528466
  • 财政年份:
    2020
  • 资助金额:
    $ 7.85万
  • 项目类别:
Complement and Thrombosis in HIT
HIT 中的补体和血栓形成
  • 批准号:
    10117675
  • 财政年份:
    2020
  • 资助金额:
    $ 7.85万
  • 项目类别:
Complement and Thrombosis in HIT
HIT 中的补体和血栓形成
  • 批准号:
    10319182
  • 财政年份:
    2020
  • 资助金额:
    $ 7.85万
  • 项目类别:
Administrative Supplement: Ayiesha Barnes
行政补充:Ayiesha Barnes
  • 批准号:
    9810534
  • 财政年份:
    2018
  • 资助金额:
    $ 7.85万
  • 项目类别:
Complement and CR2/CD21 in the Immune Pathogenesis of HIT
HIT 免疫发病机制中的补体和 CR2/CD21
  • 批准号:
    10077790
  • 财政年份:
    2018
  • 资助金额:
    $ 7.85万
  • 项目类别:
Modeling the spectrum of HIT pathobiology
HIT 病理学谱系建模
  • 批准号:
    8464632
  • 财政年份:
    2012
  • 资助金额:
    $ 7.85万
  • 项目类别:
Clinical Significance of protamine/heparin antibodies after CPB
CPB 后鱼精蛋白/肝素抗体的临床意义
  • 批准号:
    8302264
  • 财政年份:
    2011
  • 资助金额:
    $ 7.85万
  • 项目类别:
Clinical Significance of protamine/heparin antibodies after CPB
CPB 后鱼精蛋白/肝素抗体的临床意义
  • 批准号:
    8174008
  • 财政年份:
    2011
  • 资助金额:
    $ 7.85万
  • 项目类别:
Immune Dysregulation in HIT
HIT 中的免疫失调
  • 批准号:
    7815711
  • 财政年份:
    2009
  • 资助金额:
    $ 7.85万
  • 项目类别:

相似海外基金

Quantification of Neurovasculature Changes in a Post-Hemorrhagic Stroke Animal-Model
出血性中风后动物模型中神经血管变化的量化
  • 批准号:
    495434
  • 财政年份:
    2023
  • 资助金额:
    $ 7.85万
  • 项目类别:
Bioactive Injectable Cell Scaffold for Meniscus Injury Repair in a Large Animal Model
用于大型动物模型半月板损伤修复的生物活性可注射细胞支架
  • 批准号:
    10586596
  • 财政年份:
    2023
  • 资助金额:
    $ 7.85万
  • 项目类别:
A Comparison of Treatment Strategies for Recovery of Swallow and Swallow-Respiratory Coupling Following a Prolonged Liquid Diet in a Young Animal Model
幼年动物模型中长期流质饮食后吞咽恢复和吞咽呼吸耦合治疗策略的比较
  • 批准号:
    10590479
  • 财政年份:
    2023
  • 资助金额:
    $ 7.85万
  • 项目类别:
Small animal model for evaluating the impacts of cleft lip repairing scar on craniofacial growth and development
评价唇裂修复疤痕对颅面生长发育影响的小动物模型
  • 批准号:
    10642519
  • 财政年份:
    2023
  • 资助金额:
    $ 7.85万
  • 项目类别:
Diurnal grass rats as a novel animal model of seasonal affective disorder
昼夜草鼠作为季节性情感障碍的新型动物模型
  • 批准号:
    23K06011
  • 财政年份:
    2023
  • 资助金额:
    $ 7.85万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Longitudinal Ocular Changes in Naturally Occurring Glaucoma Animal Model
自然发生的青光眼动物模型的纵向眼部变化
  • 批准号:
    10682117
  • 财政年份:
    2023
  • 资助金额:
    $ 7.85万
  • 项目类别:
A whole animal model for investigation of ingested nanoplastic mixtures and effects on genomic integrity and health
用于研究摄入的纳米塑料混合物及其对基因组完整性和健康影响的整体动物模型
  • 批准号:
    10708517
  • 财政年份:
    2023
  • 资助金额:
    $ 7.85万
  • 项目类别:
A Novel Large Animal Model for Studying the Developmental Potential and Function of LGR5 Stem Cells in Vivo and in Vitro
用于研究 LGR5 干细胞体内外发育潜力和功能的新型大型动物模型
  • 批准号:
    10575566
  • 财政年份:
    2023
  • 资助金额:
    $ 7.85万
  • 项目类别:
Elucidating the pathogenesis of a novel animal model mimicking chronic entrapment neuropathy
阐明模拟慢性卡压性神经病的新型动物模型的发病机制
  • 批准号:
    23K15696
  • 财政年份:
    2023
  • 资助金额:
    $ 7.85万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
The effect of anti-oxidant on swallowing function in an animal model of dysphagia
抗氧化剂对吞咽困难动物模型吞咽功能的影响
  • 批准号:
    23K15867
  • 财政年份:
    2023
  • 资助金额:
    $ 7.85万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了